Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 | $266K | $0.00 | — | — |
| Revenue growth | — | — | — | — | — | — | — | -100.0% | — | — |
| Gross profit | — | — | — | — | — | — | $213K | — | — | — |
| Gross margin | — | — | — | — | — | — | 80.1% | — | — | — |
| Operating income | -$21.2M | -$27.3M | -$45.9M | -$55.9M | -$74.6M | -$105M | -$145M | -$40.6M | -$18.1M | $9.66M |
| Operating margin | — | — | — | — | — | — | -54663.2% | — | — | — |
| Net income | -$25.7M | -$25.8M | -$50.1M | -$56.2M | -$140M | -$176M | -$211M | -$79.8M | -$49.8M | $3.75M |
| Net margin | — | — | — | — | — | — | -79255.6% | — | — | — |
| EPS (diluted) | — | — | — | — | -$0.33 | -$0.30 | -$0.31 | -$0.10 | -$0.05 | $0.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.8M | -$26.7M | -$29.9M | -$50.5M | -$68.8M | -$118M | -$77.7M | -$25.1M | -$11.0M | -$8.77M |
| Capital expenditures | $11.9K | $11.1K | $0.00 | $26.0K | $41.0K | $122K | — | — | — | — |
| Free cash flow | -$24.8M | -$26.7M | -$29.9M | -$50.5M | -$68.8M | -$118M | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.64M | $1.78M | $1.23M | $2.61M | $14.3M | $33.9M | $4.23M | $2.54M | $3.11M | $11.9M |
| Total assets | $13.8M | $8.06M | $4.90M | $20.9M | $50.5M | $132M | $29.2M | $11.3M | $11.1M | $18.0M |
| Total liabilities | $3.58M | $9.16M | $18.1M | $29.8M | $53.0M | $153M | $124M | $121M | $128M | $114M |
| Long-term debt | — | — | — | — | — | $64.8M | $42.2M | $45.7M | $45.0M | $45.4M |
| Shareholders' equity | $10.2M | -$1.10M | -$13.2M | -$8.91M | -$2.48M | -$21.0M | -$94.4M | -$110M | -$117M | -$96.0M |
| Retained earnings | -$97.2M | -$123M | -$173M | -$229M | -$375M | -$483M | -$766M | -$842M | -$892M | -$888M |
| Shares (wtd avg diluted) | 123M | 149M | 217M | 329M | 421M | 588M | 677M | 837M | 970M | 1.24B |
Every figure is extracted from CytoDyn Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.